locamidazole

Locamidazole (LAMZ) is a **small molecule aminoindazole derivative** identified as a promising therapeutic agent for locomotor diseases such as sarcopenia and osteoporosis. It simultaneously **promotes myogenesis (muscle cell formation)** and **osteoblastogenesis (bone formation)** while **suppressing osteoclastogenesis (bone resorption)**. The drug mimics the effects of exercise by activating calcium signaling and upregulating transcription factors including **Mef2c** and **PGC-1α** in muscle and bone cells. These effects lead to increased muscle fiber width, greater muscle strength, higher bone formation rates, and reduced bone resorption. Locamidazole acts mechanistically via **calcium-PGC-1α signaling pathways**, stimulating the proliferation and differentiation of myocytes and osteoblasts and suppressing osteoclast activity[1][2][3][4][5][6][7][9][10].

Brand names

locamidazole

Other names

aminoindazole derivative